Skip to main content
SpringerLink
Log in

Author’s Reply to Shrier: “Publication Bias, With a Focus on Psychiatry: Causes and Solutions”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shrier I. Comment on: “ Publication bias, with a focus on psychiatry: causes and solutions”. CNS Drugs. 2013. doi:10.1007/s40263-013-0098-2.

  2. Turner EH. Publication bias, with a focus on psychiatry: causes and solutions. CNS Drugs. 2013;27:457–68.

    Article  PubMed  Google Scholar 

  3. Kerr N. HARKing: hypothesizing after the results are known. Pers Soc Psychol Rev. 1998;2:196.

    Article  CAS  PubMed  Google Scholar 

  4. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457–65.

    Article  CAS  PubMed  Google Scholar 

  5. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA. 2009;302:977–84.

    Article  CAS  PubMed  Google Scholar 

  6. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Chambers CD. Registered reports: a new publishing initiative at Cortex. Cortex. 2013;49:609–10.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

From 1998 to 2001, the author served as a medical reviewer at the US FDA. Subsequently, but ending in 2005, he provided outside consulting to Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. From 2004 to 2005, he was on the speaker’s bureaus of Eli Lilly, AstraZeneca, and Bristol-Myers Squibb. No sources of funding were used to prepare this manuscript.

Author information

Authors and Affiliations

  1. Behavioral Health and Neurosciences Division, Portland, USA

    Erick H. Turner

  2. Portland Veterans Affairs Medical Center, P3MHDC, 3710 SW US Veterans Hospital Rd, Portland, OR, 97239, USA

    Erick H. Turner

  3. Department of Psychiatry, Oregon Health and Science University (OHSU), Portland, OR, USA

    Erick H. Turner

  4. Department of Pharmacology, OHSU, Portland, OR, USA

    Erick H. Turner

  5. Center for Ethics in Health Care, OHSU, Portland, OR, USA

    Erick H. Turner

Authors
  1. Erick H. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erick H. Turner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turner, E.H. Author’s Reply to Shrier: “Publication Bias, With a Focus on Psychiatry: Causes and Solutions”. CNS Drugs 27, 775–776 (2013). https://doi.org/10.1007/s40263-013-0099-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-013-0099-1

Keywords

Search

Navigation